
Pneumococcal Vaccine Market Size, Share, By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, Pneumovax 23, PNEUMOSIL, and Others), Sector (Public and Private), Distribution Channel
Description
Pneumococcal Vaccine Market Size, Share, By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, Pneumovax 23, PNEUMOSIL, and Others), Sector (Public and Private), Distribution Channel (Distribution partner companies, Non-governmental organization, Government Authorities, and Others), and Region - Trends, Analysis and Forecast till 2035
The pneumococcal vaccine market is growing due to increased focus on immunization programs, awareness of vaccine-preventable diseases, and government initiatives. The market expansion is driven by the development of newer, advanced vaccines, combating serotype replacement concerns, and technological advancements in pneumococcal vaccines, which help protect against invasive diseases, reduce hospitalizations, and protect chronic respiratory diseases.
The Pneumococcal Vaccine Market Report offers an in-depth exploration of emerging market trends, driving factors, challenges, and key segments that shape the industry. It includes a thorough examination of regulatory frameworks, company profiles, and the latest industry developments. The report delves into product development, positioning strategies, and the impact of new technologies on the market landscape. By identifying challenges and opportunities, the report provides a detailed roadmap for market growth.
Report Highlights:
In June 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease caused by Streptococcus pneumonia. CAPVAXIVE was specifically designed to help protect adults against the serotypes that caused the majority of invasive pneumococcal disease (IPD) cases. The approval followed the FDA’s Priority Review of Merck’s application.
Report Analysis:
Diseases Caused by Pneumococcus:
The pneumococcal vaccine protects children from potentially serious, and even life-threatening infections caused by pneumococcus bacteria, which include (a) pneumococcal meningitis (an infection of the tissue covering the brain and spinal cord) and (b) pneumonia (lung infection). While pneumonia is a serious condition, meningitis can cause lifelong disability, or death. The Pneumococcus is also a common cause of ear infections. Children younger than 5 years and the elderly more than 65 years, are among those most at risk for the disease. Children with weak immune systems are at highest risk of infection and complications. The disease spreads when an infected person coughs or sneezes.
Segmentation:
By Vaccine Type:
Canada
U.K.
France
Russia
Italy
Spain
Netherlands
Rest of Europe
India
Japan
Australia
Indonesia
Malaysia
South Korea
Rest of Asia Pacific
Mexico
Argentina
Rest of Latin America
Israel
South Africa
Rest of Middle East & Africa
The report also includes a competitive analysis with a detailed SWOT review, examining the strengths, weaknesses, opportunities, and threats of each leading company, as well as their market share and product offerings.
List of Key Players in the Market:
Pfizer Inc.
Merck & Co., Inc.
GSK plc
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Walvax Biotechnology Co., Ltd.
Serum Institute of India Pvt. Ltd
AIM Vaccine Co., Ltd.
Precision Vax LLC
Beijing Minhai Biological Technology Co., Ltd.
Astellas Pharma Inc.
Panacea Biotec
Inventprise
Abbott
What Our Report Delivers:
Key Questions Answered in the Report.
What was the Pneumococcal Vaccine Market size in 2025?
What is projected growth rate of the Pneumococcal Vaccine Market during 2025-2035?
What are the key factors driving the Pneumococcal Vaccine Market growth?
What are leading players in the Pneumococcal Vaccine Market ?
What are the key regions analyzed in the Pneumococcal Vaccine Market ?
Which region is dominating in the Pneumococcal Vaccine Market ?
The pneumococcal vaccine market is growing due to increased focus on immunization programs, awareness of vaccine-preventable diseases, and government initiatives. The market expansion is driven by the development of newer, advanced vaccines, combating serotype replacement concerns, and technological advancements in pneumococcal vaccines, which help protect against invasive diseases, reduce hospitalizations, and protect chronic respiratory diseases.
The Pneumococcal Vaccine Market Report offers an in-depth exploration of emerging market trends, driving factors, challenges, and key segments that shape the industry. It includes a thorough examination of regulatory frameworks, company profiles, and the latest industry developments. The report delves into product development, positioning strategies, and the impact of new technologies on the market landscape. By identifying challenges and opportunities, the report provides a detailed roadmap for market growth.
Report Highlights:
- Pneumococcal vaccine market size is accounted at USD 8.8 Billion in 2025.
- Target market size is estimated to grow at a valuation of USD 15.5 Billion by 2035 and at a registered CAGR of 6.3%.
- Based on vaccine type, the pneumococcal vaccines segment is expected to dominate the pneumococcal vaccine market share.
- By product type, Prevnar 13 segment is projected to rule over the pneumococcal vaccine market.
- On the basis of sector, the public sector is the governing segment of the target market.
- According to distribution channel, the distribution partner companies is influencing the pneumococcal vaccine market.
- Geographically, North America is the region which is anticipated to lead the pneumococcal vaccine market share.
- Europe is the region, which has the pneumococcal vaccine market growing with the fastest growth rate, during the forecast period.
In June 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease caused by Streptococcus pneumonia. CAPVAXIVE was specifically designed to help protect adults against the serotypes that caused the majority of invasive pneumococcal disease (IPD) cases. The approval followed the FDA’s Priority Review of Merck’s application.
Report Analysis:
Diseases Caused by Pneumococcus:
The pneumococcal vaccine protects children from potentially serious, and even life-threatening infections caused by pneumococcus bacteria, which include (a) pneumococcal meningitis (an infection of the tissue covering the brain and spinal cord) and (b) pneumonia (lung infection). While pneumonia is a serious condition, meningitis can cause lifelong disability, or death. The Pneumococcus is also a common cause of ear infections. Children younger than 5 years and the elderly more than 65 years, are among those most at risk for the disease. Children with weak immune systems are at highest risk of infection and complications. The disease spreads when an infected person coughs or sneezes.
Segmentation:
By Vaccine Type:
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Prevnar 13
- Synoflorix
- Pneumovax 23
- PNEUMOSIL
- Others
- Public
- Private
- Distribution Partner Companies
- Non-Governmental Organization
- Government Authorities
- Others
- North America
Canada
- Europe
U.K.
France
Russia
Italy
Spain
Netherlands
Rest of Europe
- Asia Pacific
India
Japan
Australia
Indonesia
Malaysia
South Korea
Rest of Asia Pacific
- Latin America
Mexico
Argentina
Rest of Latin America
- Middle East & Africa
Israel
South Africa
Rest of Middle East & Africa
The report also includes a competitive analysis with a detailed SWOT review, examining the strengths, weaknesses, opportunities, and threats of each leading company, as well as their market share and product offerings.
List of Key Players in the Market:
Pfizer Inc.
Merck & Co., Inc.
GSK plc
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Walvax Biotechnology Co., Ltd.
Serum Institute of India Pvt. Ltd
AIM Vaccine Co., Ltd.
Precision Vax LLC
Beijing Minhai Biological Technology Co., Ltd.
Astellas Pharma Inc.
Panacea Biotec
Inventprise
Abbott
What Our Report Delivers:
- Regional & Country-Level Market Insights: Detailed market share analysis across key regions and countries to help you understand competitive positioning.
- Guidance for New Market Players: Actionable strategic recommendations for businesses entering the market, ensuring a strong foothold from the start.
- Comprehensive Market Forecasts: Reliable data projections for 2024, 2025, 2026, 2028, and 2032 to support long-term planning and investment decisions.
- In-Depth Market Dynamics: Analysis of drivers, restraints, opportunities, and emerging threats, along with challenges and high-potential investment areas.
- Data-Driven Business Strategies: Expert recommendations tailored to key market segments, backed by precise market evaluations.
- Competitive Intelligence: Mapping of prevailing industry trends and competitor strategies to identify growth opportunities.
- Detailed Company Profiles: In-depth analysis of major players, including their business strategies, financial performance, and recent developments.
- Supply Chain Innovations: Insights into the latest technological advancements and trends shaping supply chain efficiency.
Key Questions Answered in the Report.
What was the Pneumococcal Vaccine Market size in 2025?
What is projected growth rate of the Pneumococcal Vaccine Market during 2025-2035?
What are the key factors driving the Pneumococcal Vaccine Market growth?
What are leading players in the Pneumococcal Vaccine Market ?
What are the key regions analyzed in the Pneumococcal Vaccine Market ?
Which region is dominating in the Pneumococcal Vaccine Market ?
Table of Contents
168 Pages
- Pneumococcal Vaccine Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Product Type
- Market Snippet, By Sector
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Type Launch
- Merger and Acquisitions
- Impact Analysis
- PEST Analysis
- Porter’s Analysis
- Symptoms of Pneumococcal Disease
- Safe Administration of the Vaccine
- Contraindications of Pneumococcal Conjugate Vaccine
- Market Segmentation, By Vaccine Type, Forecast Period up to 10 Years, (USD Bn)
- Overview
- Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Pneumococcal Conjugate Vaccine
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Pneumococcal Polysaccharide Vaccine
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By Product Type, Forecast Period up to 10 Years, (USD Bn)
- Overview
- Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Prevnar 13
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Synflorix
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Pneumovax 23
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- PNEUMOSIL
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By Sector, Forecast Period up to 10 Years, (USD Bn)
- Overview
- Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Public
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Private
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By Distribution Channel, Forecast Period up to 10 Years, (USD Bn)
- Overview
- Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Segment Trends
- Distribution Partner Companies
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Non-Governmental Organization
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Government Authorities
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Others
- Overview
- Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
- Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)
- Overview
- Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
- Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
- Regional Trends
- North America
- Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Sector, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
- U.S.
- Canada
- Asia Pacific
- Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Sector, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
- Europe
- Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Sector, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
- Latin America
- Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Sector, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East and Africa
- Market Size and Forecast (USD Bn), By Vaccine Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Sector, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
- Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.